Kraig Biocraft Laboratories (KBLB) Cash & Equivalents (2010 - 2025)

Kraig Biocraft Laboratories has disclosed Cash & Equivalents across 15 years of filings, most recently posting $1.9 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $1.9 million, up 182.6% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.9 million (up 182.6% YoY), and the FY2025 annual result was $1.9 million, up 182.6% from the prior year.
• Cash & Equivalents came in at $1.9 million for Q4 2025 at Kraig Biocraft Laboratories, up from $596936.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $4.8 million in Q2 2022 to a low of $596936.0 in Q3 2025.
• The 5-year median for Cash & Equivalents is $2.5 million (2021), against an average of $2.5 million.
• Across the five-year window, Cash & Equivalents soared 6603.6% in 2021 and sank 73.62% in 2024, its largest moves.
• Kraig Biocraft Laboratories' Cash & Equivalents stood at $2.4 million in 2021, then soared by 64.02% to $3.9 million in 2022, then tumbled by 33.94% to $2.6 million in 2023, then tumbled by 73.62% to $673264.0 in 2024, then surged by 182.6% to $1.9 million in 2025.
• The last three Cash & Equivalents figures came in at $1.9 million (Q4 2025), $596936.0 (Q3 2025), and $785462.0 (Q2 2025), per Business Quant data.